Veracyte, Inc. (VCYT): R&D Expense
$70.81M
Year ended 2025-12-31
$93.37M
Trailing 12 months to 2026-06-30
+20.4%
3-year compound annual growth
+32.7%
5-year compound annual growth
+18.7%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $70.81M | +2.2% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $69.29M | +20.9% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $57.30M | +41.1% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $40.60M | +36.1% | 2025-02-28, From 2022-01-01 |
| 2021-12-31 | $29.84M | +73.5% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $17.20M | +15.8% | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | $14.85M | +0.2% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $14.82M | +6.8% | 2021-02-22, From 2018-01-01 |
| 2017-12-31 | $13.88M | -9.4% | 2020-02-25, From 2017-01-01 |
| 2016-12-31 | $15.32M | +19.8% | 2019-02-25, From 2016-01-01 |
| 2015-12-31 | $12.80M | +30.5% | 2018-02-27, From 2015-01-01 |
| 2014-12-31 | $9.80M | +25.5% | 2017-03-01, From 2014-01-01 |
| 2013-12-31 | $7.81M | +18.2% | 2016-03-14, From 2013-01-01 |
| 2012-12-31 | $6.61M | -1.1% | 2015-03-25, From 2012-01-01 |
| 2011-12-31 | $6.68M | n/a | 2014-03-20, From 2011-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Veracyte, Inc. (VCYT) | 2025-12-31 | $70.81M | +2.2% |
| CareDx, Inc. (CDNA) | 2025-12-31 | $71.43M | -1.5% |
| Castle Biosciences Inc (CSTL) | 2025-12-31 | $51.85M | -0.4% |
| Caris Life Sciences, Inc. (CAI) | 2025-12-31 | $101.58M | -10.8% |
| Fulgent Genetics, Inc. (FLGT) | 2025-12-31 | $53.91M | +10.4% |
| BillionToOne, Inc. (BLLN) | 2025-12-31 | $49.38M | +34.9% |
| Guardant Health, Inc. (GH) | 2025-12-31 | $364.19M | +4.7% |
| GRAIL, Inc. (GRAL) | 2025-12-31 | $195.79M | -39.3% |
| Natera, Inc. (NTRA) | 2025-12-31 | $624.11M | +54.4% |
Compare VCYT, CDNA, CSTL, CAI side by side · Screen every company in Services-Medical Laboratories ↗